Heat is breaking down medicines designed for a cooler world, warns Unitaid
Unitaid's Vincent Bretin argues that rising temperatures accelerate the chemical breakdown of medicines and calls on Britain to lead on a fix that would benefit all countries.
Heat is accelerating the chemical breakdown of medicines, and the drugs now used around the world were not designed for the climate they are increasingly exposed to, according to an opinion piece by Vincent Bretin of Unitaid. Published around the COP31 climate summit in Antalya, the piece argues that the global medicines system was built for conditions that no longer exist, and that the gap between those assumptions and today's warmer reality is a public health problem.
The central claim is that higher temperatures speed up the degradation of pharmaceutical products. Medicines are typically tested and stored against standards that assume a particular range of conditions, and when they are transported or kept in places that become hotter, their active ingredients can lose strength over time. Bretin's argument is that this risk is not evenly spread: countries already facing high temperatures and limited cold-chain infrastructure are the most exposed, even though they often have the least capacity to respond.
Bretin writes that the United Kingdom already contributes to part of the answer through existing funding, and he argues that Britain should take a leading role so that the benefits reach every country rather than only those able to pay for specialised solutions. The notes available for this report do not specify how much money Britain provides, which programmes it supports, or what concrete policy steps the piece proposes, so the scale and form of any such leadership remain unclear from the material at hand.
The available text is a standfirst and the body of the piece was not supplied, meaning that specific figures, named studies and particular drugs affected by heat are not confirmed here. What the piece does make clear is its framing: that climate change is not only a matter of weather and energy, but also of the reliability of the medicines that health systems depend on. As global temperatures rise, the question of whether treatments remain effective in hot conditions is likely to become more pressing for governments, international health agencies and manufacturers alike.
Source: independent.co.uk
43
